On 26 August 2026, the FDA approved Rasonque (daraxonrasib), a targeted therapy for certain patients with metastatic pancreatic cancer. It is a RAS inhibitor. Who is it for? The approval
Category: Drug of the week
FDA’s TEMPO Pilot: A Boon for Chronic Disease CareFDA’s TEMPO Pilot: A Boon for Chronic Disease Care
FDA just launched TEMPO, a digital health strategy that can come as a boon for people with chronic ailments.
Durvalumab Approved by FDA: Here’s What You Should KnowDurvalumab Approved by FDA: Here’s What You Should Know
Durvalumab, a monoclonal antibody gets a nod from the FDA to be used in resectable stomach cancers. Read more for full story.
Amoxicillin-Clavulanate- Latest ResearchAmoxicillin-Clavulanate- Latest Research
This week featuring drug of the week is Amoxicillin-Clavunate, a pediatric combination antibacterial drug. Click to read full post.
Semaglutide- boon or bane for weight lossSemaglutide- boon or bane for weight loss
Explore how GLP-1 receptor agonists are transforming healthcare. Read more in this week’s Drug of the Week on BioDiaries.
Letrozole: From Breast Cancer to Fertility and BeyondLetrozole: From Breast Cancer to Fertility and Beyond
In today's drug of the week series, explore letrozole’s role in cancer treatment, fertility, and emerging research breakthroughs.